Path: ...!feeder3.eternal-september.org!i2pn.org!i2pn2.org!.POSTED!not-for-mail
From: manta103g@gmail.com (darius)
Newsgroups: soc.culture.polish
Subject: Kolejna analiza kartoteki medycznej pacjentki, =?UTF-8?B?a3TDs3JhIHptYXI=?=
 =?UTF-8?B?xYJhIHBvIHphc3pjemVwaWVuaXUgbmEgQ09WSUQtMTk=?=
Date: Tue, 31 Dec 2024 23:08:53 +0000
Organization: novaBBS
Message-ID: <182effd08e56f154600e83511d7727e6@www.novabbs.com>
MIME-Version: 1.0
Content-Type: text/plain; charset=utf-8; format=flowed
Content-Transfer-Encoding: 8bit
Injection-Info: i2pn2.org;
	logging-data="1405111"; mail-complaints-to="usenet@i2pn2.org";
	posting-account="2ziXmaI3LavkZj56FXjLrM7mC0F1I2GCdPVHQb5yvsw";
User-Agent: Rocksolid Light
X-Rslight-Posting-User: 489b6c3a5945b08c369609b0686e9eb2a340a22d
X-Spam-Checker-Version: SpamAssassin 4.0.0
X-Rslight-Site: $2y$10$/9GkOeCv.3Z6E/Lty.iQ9ORMMvzWqR8DY/L2hv8FyMIXUsIsQqX0a
Bytes: 4762
Lines: 91

The provided medical record details a case involving a 98-year-old
female patient who experienced severe health complications shortly after
receiving a COVID-19 vaccination. Below is a detailed analysis of the
key elements within the record:
Patient Information

    Age: 98 years
    Sex: Female
    Location: Foreign
    Vaccination Date: November 14, 2024
    Onset of Symptoms: November 14, 2024 (same day as vaccination)
    Date of Death: November 16, 2024 (2 days after onset)

Vaccination History

    Vaccine: Pfizer-BioNTech COVID-19 Vaccine (COMIRNATY) (specific
variant: OMICRON (JN.1))
    Dose: 1 (first dose of the vaccination series)
    Present Condition: The patient had previously completed a
vaccination series prior to this booster.

Reported Symptoms and Health Issues

    Symptoms on Record:
        Cardio-respiratory arrest (fatal)
        Pyrexia (elevated body temperature, approximately 39°C)
        Blood pressure and glycosylated hemoglobin (HbA1c) were reported
to be under control.

    Preexisting Conditions:
        Hypertension
        Diabetes mellitus (with controlled glycosuria)
        Sleep disorder

Timeline of Events

    November 14, 2024: Patient received the COVID-19 vaccine and
reported developing a fever (pyrexia) the same evening.
    November 15, 2024: The patient's condition continued to deteriorate,
and her temperature stabilized at around 39°C.
    November 16, 2024: The patient experienced cardio-respiratory arrest
and subsequently died.

Medical Interventions

    Antipyretics were administered to manage the fever, but the outcome
remained poor, leading to hospitalization (though it is unclear for how
long).

Reporting and Outcomes

    Death: The cause of death was documented as cardio-respiratory
arrest, with indications that this event occurred shortly after
vaccination.
    Life Threatening Assessment: Although labeled as “no” for
life-threatening status initially, the eventual outcome was fatal,
highlighting a potentially serious turn of events.
    Causality Assessment: The reporting physician indicated a plausible
connection between the increase in body temperature (pyrexia) and the
vaccination. However, the association between cardio-respiratory arrest
and the vaccine was less clearly defined and left open for further
investigation.

Conclusion

The record highlights the fragility and risks associated with
vaccination in very elderly individuals, particularly those with
comorbid conditions. Key points include:

    Vaccination Risks in Elderly: Given the advanced age of the patient,
her health complications (hypertension and diabetes), the risk of
adverse events post-vaccination may be heightened. The quick onset of
severe symptoms raises concerns about the safety profile of the vaccine
in this demographic.
    Clinical Monitoring: Proper monitoring after vaccination, especially
in high-risk populations, is crucial. The patient's fever indicates a
potential reaction that required more careful evaluation by healthcare
professionals.
    Implications for Future Vaccination Protocols: This case may prompt
healthcare providers to reassess vaccination protocols and monitoring
practices for elderly patients, particularly those with complex health
issues.

Recommendations for Further Evaluation

    Follow-Up Investigation: An autopsy or further investigative
measures could provide insights into the direct causes of death and
clarify any underlying issues exacerbated by the vaccine.
    Comprehensive Review: Continued aggregation and analysis of similar
cases would help in understanding the risk factors associated with
vaccination in this age group and contribute to ongoing safety
evaluations for vaccines.